Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Gliosarcoma 7Central Nervous System Neoplasms 7Lymphoma 5Breast Neoplasms 5Prostatic Neoplasms 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Kidney Neoplasms 4Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Head and Neck Neoplasms 3Brain Neoplasms 3Urogenital Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Multiple Myeloma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Large Cell 2Adenocarcinoma of Lung 2

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × motexafin gadolinium × Clear all
NCT00129844 2008-08-20

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Pharmacyclics LLC.

Phase 2 Completed
108 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡